Hypertension Experts Push For New Trial Of Renal Denervation To Show Efficacy
This article was originally published in The Gray Sheet
Since Medtronic’s sham-controlled SYMPLICITY HTN-3 trial of its Symplicity renal denervation device failed to meet its primary efficacy endpoint, manufacturers developing renal denervation systems have been working with researchers and FDA to map the next steps in researching and developing this hypertension therapy.
You may also be interested in...
The majority of FDA’s circulatory systems devices panel agreed that ReCor’s Paradise ultrasound renal denervation system offers a safe and effective therapy for patients with hypertension. The panel’s endorsement means ReCor will likely be the first company to reach the US market with an RDN system.
News We’re Watching: ReCor And Medtronic Head To RND Panel, Clearances For Anika And Sequel, ZimVie And Brainlab Partner
This week, the US FDA geared up for a renal denervation panel meeting; a microbiology panel meeting was announced; and a hyaluronic acid patch to promote rotator cuff healing, a novel spiral tampon, and a tibial neuromodulation device to treat incontinence all won FDA clearance.
The late-breaking clinical trial presentations at this year’s Transcatheter Cardiovascular Therapeutics conference in Boston included new results from trials of three different minimally invasive approaches to treat uncontrolled hypertension.